Market Overview

UPDATE: Raymond James Upgrades Amsurg Following Sheridan Health Acquisition

Related AMSG
UBS Sees $43-$44 Deal Value For Potential TeamHealth Sale
Benzinga's M&A Chatter for Tuesday October 4, 2016
60% Return From Reynolds' Smoking Hot Opportunity (Seeking Alpha)

In a report issued Friday, Raymond James upgraded its rating of Amsurg (NASDAQ: AMSG) from Market Perform to Strong Buy with a target price of $60.

Analyst John W. Ransom has raised his estimates for Amsurg with its acquisition of Sheridan Health on Thursday. This merger should help boost organic and EPS growth, as well.

Ransom also raised his EPS estimate from $2.77 to $3.15 for 2015.

Amsurg will open Friday at $45.74.

Latest Ratings for AMSG

Sep 2016CitigroupInitiates Coverage onBuy
Jun 2016Wells FargoInitiates Coverage onMarket Perform
Apr 2016MizuhoInitiates Coverage onBuy

View More Analyst Ratings for AMSG
View the Latest Analyst Ratings

Posted-In: John W. RansomAnalyst Color News Upgrades Price Target Analyst Ratings


Related Articles (AMSG)

View Comments and Join the Discussion!